Young-Onset Colon Cancer and Recurrence Risk by Gene Expression
Open Access
- 5 February 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 112 (11), 1170-1173
- https://doi.org/10.1093/jnci/djaa019
Abstract
The incidence and mortality from colorectal cancer in younger adults (younger than 55 years) is increasing. We reviewed the complete database of a gene-expression test, Oncotype DX Colon Recurrence Score test, to determine age-related differences in recurrence score (RS) and single-gene results (7 cancer-related of the 12-gene assay). We included 20 478 stage II and III A and B colon cancer patients submitted to Genomic Health. RS results were grouped by low-, intermediate-, and high-risk groups. Single-gene scores were described using median and interquartile range. Of all patients 72.5% and 72.6% of those younger than 40 years had low-risk RS. Comparing older with younger patients, RS or single-gene expression did not differ by age group or stage. Young-onset colon cancer does not differ by expression of the RS component genes. Most patients with stage II and III colon cancer have low-risk disease as measured by the 12-gene assay, regardless of age.Funding Information
- Genomic Health, Inc
This publication has 9 references indexed in Scilit:
- Chemotherapy Use and Survival Among Young and Middle-Aged Patients With Colon CancerJAMA Surgery, 2017
- Patterns of Sociodemographic and Clinicopathologic Characteristics of Stages II and III Colorectal Cancer Patients by Age: Examining Potential Mechanisms of Young-Onset DiseaseJournal of Cancer Epidemiology, 2017
- 12-Gene Recurrence Score Assay Stratifies the Recurrence Risk in Stage II/III Colon Cancer With Surgery Alone: The SUNRISE StudyJournal of Clinical Oncology, 2016
- Overtreatment of Young Adults With Colon CancerJAMA Surgery, 2015
- Increasing Disparities in the Age-Related Incidences of Colon and Rectal Cancers in the United States, 1975-2010JAMA Surgery, 2015
- Validation of the 12-Gene Colon Cancer Recurrence Score in NSABP C-07 As a Predictor of Recurrence in Patients With Stage II and III Colon Cancer Treated With Fluorouracil and Leucovorin (FU/LV) and FU/LV Plus OxaliplatinJournal of Clinical Oncology, 2013
- Biologic Determinants of Tumor Recurrence in Stage II Colon Cancer: Validation Study of the 12-Gene Recurrence Score in Cancer and Leukemia Group B (CALGB) 9581Journal of Clinical Oncology, 2013
- Validation Study of a Quantitative Multigene Reverse Transcriptase–Polymerase Chain Reaction Assay for Assessment of Recurrence Risk in Patients With Stage II Colon CancerJournal of Clinical Oncology, 2011
- Translating tumor biology into personalized treatment planning: analytical performance characteristics of the Oncotype DX®Colon Cancer AssayBMC Cancer, 2010